Ovid Therapeutics
@OvidRx
Followers
2K
Following
482
Statuses
2K
Conquering brain conditions with courageous science. Our guidelines: https://t.co/gD8IS1laCV
New York, NY
Joined April 2015
Neuron hyperexcitability can be the root cause of many brain disorders. KCC2 activation restores balance between excitation & inhibition, making it a promising approach. As Dr. Moss shares, directly activating KCC2 could be a game-changer, reducing off-target side effects.
0
2
3
Ovid CEO @jmaxlevin recently moderated a panel at @LongwoodLeaders San Francisco CEO, highlighting the importance of uniting the biopharma industry to drive greater value and improve patient outcomes.
0
1
1
Ovid President & COO Meg Alexander recently joined a panel at @LongwoodLeaders San Francisco CEO to discuss the importance of resilient company cultures in biopharma ahead of #JPM2025.
0
1
1
Today we honor Dr. King’s legacy of justice, unity and resilience. His message reminds us that real change requires collective action and perseverance – a message that continues to inspire our work every day.
0
0
0
Honored to be named one of the 10 biotechs to watch in 2025 by @labiotech_eu! At Ovid, we’re advancing therapies that target hyperexcited neurons, aiming to restore balance and transform treatments for CNS conditions. Read more:
0
0
0
@jmaxlevin, CEO, & Meg Alexander, President & COO, spoke with @INVIVOnow's Jo Shorthouse about advancing KCC2 activators—the "master switch" in neurology. Dr. Levin: "The opportunity is just starting to open up." Read more: #Neurology #KCC2
0
1
2
Ovid President and COO Meg Alexander will join a panel of industry leaders at the @LongwoodLeaders San Francisco CEO event to delve into the powerful role of company culture in driving success. Learn more:
0
1
1
CEO @jmaxlevin will moderate a panel at the upcoming @LongwoodLeaders San Francisco CEO event, just ahead of #JPM2025. Industry leaders will discuss how uniting biopharma accelerates patient-focused innovation. Learn more:
1
3
7
Happy Holidays from Ovid Therapeutics! Grateful for the support and friendship of patients, families, industry professionals, and partners. Your strength and collaboration inspire our work. Wishing you a joyful holiday season and a bright, hopeful New Year!
0
1
2
As 2024 ends, we reflect on a year of progress and commitment to our patient community. Watch our Recap Video to relive this year's highlights. Thank you to everyone who’s been part of our journey. Here’s to making even greater strides in 2025! ⭐
1
3
4
Directly activating KCC2 could transform treatments for neuropsychiatric, neurodevelopmental and neurodegenerative diseases. Our President & COO, Meg Alexander, shares more below. #KCC2 #Neuroscience
0
2
5
Ovid CEO @jmaxlevin and President & COO Meg Alexander discuss unlocking KCC2's potential to treat a range of neuro conditions in a recent @BioCentury article. Our lead candidate from our KCC2 library, OV350, will move into phase 1 next year. Learn more:
0
2
4
In this @Labiotech_eu article, Ovid CEO @jmaxlevin predicts breakthroughs for neurology similar to the GLP-1 revolution. #Biotech #Innovation
0
2
2
Ovid’s CSO, Zhong Zhong, will present at the 2024 @AmEpilepsySoc Annual Meeting. Learn more at this link: #AES2024
0
1
4
Ovid’s SVP of Clinical Development, Julia Tsai, will present at this year’s @AmEpilepsySoc Annual Meeting. View details below and at this link: #AES2024
0
1
1
Toshiya Nishi, Ovid’s Senior Director of Drug Discovery, will be presenting on our KCC2 activator, OV350, at the 2024 @AmEpilepsySoc Annual Meeting. If you’re attending AES, come speak with him about the latest preclinical research in KCC2! Learn more:
0
1
3
Ovid will be presenting multiple posters supporting our pipeline programs targeting neuronal hyperexcitability at the 2024 @AmEpilepsySoc Annual Meeting. Learn more: #AES2024
0
1
4
November is Epilepsy Awareness Month. 💜 We spoke with Beth Dean, CEO of @CureEpilepsy, during their SUDEP workshop hosted at our NYC office about the importance of awareness, advocacy, and advancing research. #EpilepsyAwarenessMonth
0
1
2
Did you know KCC2 is considered one of the most exciting therapeutic targets in neuroscience today? Directly activating KCC2 may open new avenues for potential treatments across a range of CNS conditions. Learn more about KCC2 below & at this link:
0
1
1
Today, Raquel Cabo joins a panel at @LifeSciEvents' DEI Forum, highlighting how our patient-centered, inclusive communications and outreach strategies have fostered stronger connections with patient communities. Learn more & register for the event:
0
1
1